Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor–positive breast cancer

被引：0

作者：

Connie Lau ^{[1
]}

Krista LaBorde ^{[1
]}

Bilqees Fatima ^{[2
]}

Shahad S. Alfartosy ^{[1
]}

Susan Abughosh ^{[2
]}

Rodrigo De La Torre ^{[3
]}

Erika N. Brown ^{[3
]}

Meghana V. Trivedi ^{[1
]}

机构：

[1] University of Houston College of Pharmacy,Department of Pharmacy Practice and Translational Research

[2] University of Houston College of Pharmacy,Department of Pharmaceutical Health Outcomes and Policy

[3] Houston Methodist Willowbrook Hospital,undefined

来源：

关键词：

Breast cancer; Hormone receptor-positive/HER2-negative; CDK4/6 inhibitors; Endocrine therapy; Medication adherence; Specialty pharmacy;

D O I：

10.1007/s10549-025-07701-x

中图分类号：

学科分类号：

摘要：

引用

页码：71 / 78

页数：7